Given the current concern that injection of anti–vascular endothelial growth factor (anti-VEGF) may lead to increased risks of thromboembolic events,28,29 knowledge of the accurate influence of AMD on mortality risk, especially CVD mortality, is warranted. This evidence concerns the gene VEGFA and age-related macular degeneration.